Neurofibroma classification: Difference between revisions
Jump to navigation
Jump to search
Sara Mohsin (talk | contribs) |
Sara Mohsin (talk | contribs) |
||
Line 12: | Line 12: | ||
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Characteristics/Description | ! style="background:#4479BA; color: #FFFFFF;" align="center" + |Characteristics/Description | ||
|- | |- | ||
| style="background:#DCDCDC;" align="center" + |[[Cutaneous]]/[[Dermal]]/[[Localized disease|Localized]] (90%) | | style="background:#DCDCDC;" align="center" + |'''[[Cutaneous]]/[[Dermal]]/[[Localized disease|Localized]]''' (90%) | ||
| | | | ||
* Most common | * Most common | ||
Line 25: | Line 25: | ||
* Mostly solitary and sporadic, not associated with NF1 | * Mostly solitary and sporadic, not associated with NF1 | ||
|- | |- | ||
| style="background:#DCDCDC;" align="center" + |[[Subcutaneous]] | | style="background:#DCDCDC;" align="center" + |[[Subcutaneous|'''Subcutaneous''']] | ||
| | | | ||
* Common | * Common | ||
Line 32: | Line 32: | ||
* They are often a form of [[Plexiform neurofibroma|plexiform neurofibromas]] | * They are often a form of [[Plexiform neurofibroma|plexiform neurofibromas]] | ||
|- | |- | ||
| style="background:#DCDCDC;" align="center" + |[[Diffuse]] | | style="background:#DCDCDC;" align="center" + |[[Diffuse|'''Diffuse''']] | ||
(superficial) | '''(superficial)''' | ||
| | | | ||
* Superficial | * Superficial | ||
Line 46: | Line 46: | ||
* Solitary lesions and not related to any inherited condition | * Solitary lesions and not related to any inherited condition | ||
|- | |- | ||
| style="background:#DCDCDC;" align="center" + |[[Intramuscular]] | | style="background:#DCDCDC;" align="center" + |[[Intramuscular|'''Intramuscular''']] | ||
| | | | ||
* Common | * Common | ||
Line 55: | Line 55: | ||
* Sometimes can occur as [[Plexiform neurofibroma|plexiform neurofibromas]] in form of chains or networks | * Sometimes can occur as [[Plexiform neurofibroma|plexiform neurofibromas]] in form of chains or networks | ||
|- | |- | ||
| style="background:#DCDCDC;" align="center" + |[[Plexiform neurofibroma|Plexiform]]/Intraneural | | style="background:#DCDCDC;" align="center" + |'''[[Plexiform neurofibroma|Plexiform]]/Intraneural''' | ||
(deep) | '''(deep)''' | ||
| | | | ||
* Deep | * Deep | ||
Line 68: | Line 68: | ||
* Disfiguring | * Disfiguring | ||
* Affects function due to sheer size as well as neurovascular compromise | * Affects function due to sheer size as well as neurovascular compromise | ||
* Upto 5% risk of malignant transformation | |||
*Plexiform neurofibroma exhibits following features on T2-weighted MRI: | *Plexiform neurofibroma exhibits following features on T2-weighted MRI: | ||
**Target sign (low signal intensity centrally with a ring of high signal intensity peripherally) | **Target sign (low signal intensity centrally with a ring of high signal intensity peripherally) | ||
Line 73: | Line 74: | ||
**May appear as a larger and more infiltrating mass with lobulated borders with inhomogeneous enhancement | **May appear as a larger and more infiltrating mass with lobulated borders with inhomogeneous enhancement | ||
|- | |- | ||
| style="background:#DCDCDC;" align="center" + |Pigmented | | style="background:#DCDCDC;" align="center" + |'''Pigmented''' | ||
| | | | ||
* Neurofibroma with melanin-bearing pigmented cells, usually only appreciated microscopically | * Neurofibroma with melanin-bearing pigmented cells, usually only appreciated microscopically | ||
Line 86: | Line 87: | ||
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Characteristics/Description | ! style="background:#4479BA; color: #FFFFFF;" align="center" + |Characteristics/Description | ||
|- | |- | ||
| style="background:#DCDCDC;" align="center" + |[[Diffuse]] [[Plexiform neurofibroma|Plexiform]] | | style="background:#DCDCDC;" align="center" + |'''[[Diffuse]] [[Plexiform neurofibroma|Plexiform]]''' | ||
| | | | ||
* It extends through the [[skin]] into [[fascia]] and [[muscle]] | * It extends through the [[skin]] into [[fascia]] and [[muscle]] | ||
Line 94: | Line 95: | ||
* May have a large [[café au lait spot]] “above” it | * May have a large [[café au lait spot]] “above” it | ||
|- | |- | ||
| style="background:#DCDCDC;" align="center" + |[[Nodular]] [[Plexiform neurofibroma|Plexiform]] | | style="background:#DCDCDC;" align="center" + |'''[[Nodular]] [[Plexiform neurofibroma|Plexiform]]''' | ||
| | | | ||
* Usually involves [[nerves]] coming off the [[spinal cord]] or off of larger [[nerves]] (such as [[sciatic nerve]]) | * Usually involves [[nerves]] coming off the [[spinal cord]] or off of larger [[nerves]] (such as [[sciatic nerve]]) |
Revision as of 17:06, 29 March 2019
Neurofibroma Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Neurofibroma classification On the Web |
American Roentgen Ray Society Images of Neurofibroma classification |
Risk calculators and risk factors for Neurofibroma classification |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sara Mohsin, M.D.[2]
Overview
Neurofibroma may be classified into 5 subtypes: cutaneous/dermal/localized, subcutaneous, diffuse, intramuscular, and plexiform neurofibroma. Plexiform neurofibromas may be further sub-classified into diffuse and nodular plexiform.
Classification
Neurofibroma may be classified into following 5 subtypes:[1][2][3]
Types of neurofibromas | Characteristics/Description |
---|---|
Cutaneous/Dermal/Localized (90%) |
|
Subcutaneous |
|
Diffuse
(superficial) |
|
Intramuscular |
|
Plexiform/Intraneural
(deep) |
|
Pigmented |
|
Plexiform neurofibromas can be further subclassified into following:[4]
Types of neurofibromas | Characteristics/Description |
---|---|
Diffuse Plexiform | |
Nodular Plexiform |
|
References
- ↑ Neurofibroma. Libre Pathology 2015. http://librepathology.org/wiki/index.php/Neurofibroma#cite_note-pmid15486243-2 Accessed on November 17, 2015
- ↑ http://www.nfmidwest.org/wp-content/uploads/2016/03/Neurofibromas.pdf
- ↑ https://pubs.rsna.org/doi/10.1148/rg.24si035170#REF8
- ↑ http://www.nfmidwest.org/wp-content/uploads/2016/03/Neurofibromas.pdf